1. Home
  2. WST vs ARCC Comparison

WST vs ARCC Comparison

Compare WST & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WST
  • ARCC
  • Stock Information
  • Founded
  • WST 1923
  • ARCC 2004
  • Country
  • WST United States
  • ARCC United States
  • Employees
  • WST N/A
  • ARCC N/A
  • Industry
  • WST Medical/Dental Instruments
  • ARCC Finance/Investors Services
  • Sector
  • WST Health Care
  • ARCC Finance
  • Exchange
  • WST Nasdaq
  • ARCC Nasdaq
  • Market Cap
  • WST 20.1B
  • ARCC 15.8B
  • IPO Year
  • WST N/A
  • ARCC 2004
  • Fundamental
  • Price
  • WST $262.43
  • ARCC $20.23
  • Analyst Decision
  • WST Strong Buy
  • ARCC Buy
  • Analyst Count
  • WST 9
  • ARCC 11
  • Target Price
  • WST $354.50
  • ARCC $22.50
  • AVG Volume (30 Days)
  • WST 784.7K
  • ARCC 4.3M
  • Earning Date
  • WST 10-23-2025
  • ARCC 10-28-2025
  • Dividend Yield
  • WST 0.34%
  • ARCC 9.50%
  • EPS Growth
  • WST 0.17
  • ARCC N/A
  • EPS
  • WST 6.75
  • ARCC 1.99
  • Revenue
  • WST $3,017,900,000.00
  • ARCC $3,018,000,000.00
  • Revenue This Year
  • WST $6.97
  • ARCC $3.68
  • Revenue Next Year
  • WST $6.11
  • ARCC $5.10
  • P/E Ratio
  • WST $38.70
  • ARCC $10.14
  • Revenue Growth
  • WST 4.92
  • ARCC 2.72
  • 52 Week Low
  • WST $187.43
  • ARCC $18.26
  • 52 Week High
  • WST $348.90
  • ARCC $23.84
  • Technical
  • Relative Strength Index (RSI)
  • WST 40.53
  • ARCC 49.13
  • Support Level
  • WST $262.48
  • ARCC $19.85
  • Resistance Level
  • WST $280.11
  • ARCC $20.53
  • Average True Range (ATR)
  • WST 9.13
  • ARCC 0.37
  • MACD
  • WST -2.99
  • ARCC 0.04
  • Stochastic Oscillator
  • WST 9.48
  • ARCC 39.33

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.

Share on Social Networks: